Pharmafile Logo
Pharmafocus logo
Advanced Search
pfizer_enbrel

New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile

July 7, 2016
Research and Development, Sales and Marketing Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars

Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in …

News
logo_400x400

Biogen and AbbVie’s Zinbryta gets European backing to treat multiple sclerosis

July 7, 2016
Research and Development, Sales and Marketing Biogen, drug approval, european union, multiple sclerosis, zinbryta

Biogen (Nasdaq: BIIB) and Abbvie’s (NYSE: ABBV) once-monthly Zinbryta (daclizumab) has been approved in European Union for treatment of multiple …

News
shire_image_4

Shire gets extended market authorization in Europe for drug to treat children with a rare gastrointestinal condition

July 7, 2016
Research and Development, Sales and Marketing European Commission, Revestive, Shire, market authorisation, short bowel syndrome

UK drugmaker Shire (LSE: SHP) said the European Commission has granted extension of Market Authorization for Revestive (teduglutide) to treat …

News

Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund

July 7, 2016
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif

The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …

News
takeda_world

Takeda says its cancer drug Adcetris gets European backing in for hodgkin lymphoma

July 6, 2016
Research and Development European Commission, Takeda, drug trial, lymphoma

Takeda Pharmaceutical (TSE: 4502) said the European Commission has extended the marketing authorization for its Adcetris (brentuximab vedotin) to treat …

News
clinical_trial_3

Merck and Pfizer begin Phase III trials for avelumab in ovarian cancer

July 6, 2016
Research and Development Merck, Pfizer, avelumab

Merck (KGaA, Darmstadt) and Pfizer (NYSE: PFE) have announced the initiation of the first Phase III study of investigational compound, …

News

Wickham Laboratories Announces New In Vitro Pyrogenicity Testing Method

July 6, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Wickham Laboratories is pleased to announce the introduction of a new in vitro test method, the Monocyte Activation Test, for …

News
Press release
az_logo

AstraZeneca trigger $10 million milestone payment for Heptares in immuno-oncology candidate

July 6, 2016
Research and Development, Sales and Marketing AstraZeneca, Heptares

AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics after the first patient was …

News

Sanofi says to co-develop Zika vaccine with US government

July 6, 2016
Research and Development, Sales and Marketing Sanofi, US government, Vaccine, Zika virus, drug development, research

French drugmaker Sanofi (Euronext: SAN) said it will co-develop a Zika vaccine candidate with the US government.  No financial details …

News

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million

July 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, cormorant

Bristol-Myers Squibb (NYSE: BMY) has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it …

News

Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal

July 6, 2016
Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer

Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …

News

Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation

UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …

News

UCB scores Japanese approval for seizure therapy, Vimpat

July 5, 2016
Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese

UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …

News

Sanofi, Regeneron say cholesterol drug Praluent approved in Japan

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt

Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …

News
eisa0005

Eisai launches cancer drug Lenvatinib in Mexico

July 4, 2016
Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch

Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …

News
allergan

Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators

July 4, 2016
Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial

Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …

News
amgen_hq

Amgen says its blood cancer drug gets European backing for extended indication

July 4, 2016
Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial

Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …

News
mr058666-web

Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer

July 4, 2016
Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study

Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …

News
stocks1

Weekly Movers: Regulus, Nymox, Akers…

July 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks

Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …

Feature
astrazeneca_building_white

AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront

July 1, 2016
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development

UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026